Last reviewed · How we verify
NCT05182359: PORTRAIT-DM
Pragmatic Impact of Proteomic Risk Stratification in Diabetes Mellitus
NA trial testing SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test in Type 2 Diabetes in 150 participants. Completed in 31 March 2023.
31 March 2023
Quick facts
| Lead sponsor | University Hospitals Cleveland Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 150 |
| Start date | 26 January 2022 |
| Primary completion | 31 March 2023 |
| Estimated completion | 31 March 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SomaSignal Cardiovascular Risk in Type 2 Diabetes (CVD-T2D) Test and SomaSignal Metabolic Factors test
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
University Hospitals Cleveland Medical Center
Who can join
Adults 40 to 89, any sex, with Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Single-center, prospective, 2:1 randomized controlled parallel-group study, with an open label extension to evaluate SomaSignal Informed Medical Management (informed) versus Standard of Care (uninformed).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Crossing the Halfway Point: Aptamer-Based, Highly Multiplexed Assay for the Assessment of the Proteome.
Kraemer S, Schneider DJ, Paterson C, Perry D, et al · · 2024 · cited 22× · PMID 39038188 · DOI 10.1021/acs.jproteome.4c00411
Verify or expand the search:
- PubMed search for NCT05182359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other University Hospitals Cleveland Medical Center trials
Trials by the same sponsor.
- NCT06997198 — Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities · Phase 4 · not yet recruiting
- NCT07379814 — Rectus Abdominis Detrusor Myoplasty for Urinary Retention · not yet recruiting
- NCT07499648 — Baby Steps to Care · NA · not yet recruiting
- NCT07497737 — OMT for Adhesive Capsulitis · Phase 4 · not yet recruiting
- NCT06523166 — Direct Comparison of Cardiac CT With TEE to Evaluate Watchman FLX LAA Occluder Device Characteristics · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05182359 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospitals Cleveland Medical Center
- Last refreshed: 3 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05182359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing